Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bucindolol has serotonin and alpha-adrenoceptor blocking properties.

J F Marwood, G S Stokes

    Journal of Cardiovascular Pharmacology
    |January 1, 1985
    PubMed
    Summary

    Bucindolol exhibits novel dual antagonist properties, acting as a beta-adrenoceptor antagonist with additional weak serotonin (5-HT) and alpha-adrenergic antagonist effects. This combination contributes to its blood pressure-lowering action through vasodilation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    An identification of low back pain groups using biobehavioral variables.

    Journal of occupational rehabilitation·2013
    Same author

    New Agent in the Treatment of Cystinuria: N-acetyl-D-penicillamine.

    British medical journal·2010
    Same author

    Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism.

    Journal of hypertension·2001
    Same author

    Influence of angiotensin converting enzyme (ACE) genotype on interpretation of diagnostic tests for serum ACE activity.

    Australian and New Zealand journal of medicine·2000
    Same author

    A controlled study of the effects of isosorbide mononitrate on arterial blood pressure and pulse wave form in systolic hypertension.

    Journal of hypertension·2000
    Same author

    Effect of angiotensin II receptor blockade on the interaction between enalaprilat and doxazosin in rat tail arteries.

    Clinical and experimental pharmacology & physiology·1998

    Area of Science:

    • Pharmacology
    • Cardiovascular Research

    Background:

    • Bucindolol is a beta-adrenoceptor antagonist known to lower blood pressure through vasodilation.
    • The precise mechanisms underlying bucindolol's antihypertensive effects require further elucidation.

    Purpose of the Study:

    • To investigate the pharmacological mechanisms of bucindolol's antihypertensive action.
    • To characterize bucindolol's interactions with serotonin (5-HT) and alpha-adrenergic receptors.

    Main Methods:

    • Utilized the isolated perfused rat tail artery preparation.
    • Assessed dose-response curves for serotonin (5-HT) and phenylephrine (PE) in the presence of bucindolol.
    • Determined pA2 values and calculated potency ratios to identify receptor antagonism.

    Main Results:

    Related Experiment Videos

    • Bucindolol demonstrated competitive antagonism against both 5-HT and phenylephrine (PE).
    • pA2 values indicated weak serotonin antagonist (5.9 +/- 0.2) and alpha-adrenergic antagonist (7.18 +/- 0.10) properties.
    • Bucindolol reduced maximal response to 5-HT but not PE, suggesting overlapping receptor binding sites.

    Conclusions:

    • Bucindolol possesses a novel combination of beta-adrenoceptor, weak serotonin, and alpha-adrenergic antagonist properties.
    • These combined antagonist actions likely contribute to bucindolol's antihypertensive efficacy via vasodilation.
    • Findings support the hypothesis of overlapping binding sites between 5-HT and alpha-adrenoceptors on vascular smooth muscle cells.